

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7228066

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YAO-LIN SUN	01/08/2021
LUNGHU WANG	01/08/2021
CHANGJUNG WU	01/08/2021
CHUANDER HUANG	09/26/2018
RECEIVING PARTY DATA	
Name:	KRISAN BIOTECH CO., LTD.
Street Address:	5F, NO. 30, LANE 31, SECTION 1, HUANGDON ROAD, XINSHI DISTRICT
City:	TAINAN CITY
State/Country:	TAIWAN
Postal Code:	74146
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17580428
CORRESPONDENCE DATA	
Fax Number:	(816)753-1536
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8167531000
Email:	patentdocketing@polsinelli.com, ckcampbell@polsinelli.com
Correspondent Name:	POLSINELLI PC
Address Line 1:	900 W. 48TH PLACE, SUITE 900
Address Line 4:	KANSAS CITY, MISSOURI 64112
ATTORNEY DOCKET NUMBER:	109559-715740
NAME OF SUBMITTER:	CHRISTINA CAMPBELL
SIGNATURE:	/Christina Campbell/
DATE SIGNED:	03/16/2022
Total Attachments: 4	
source=109559-715740 Executed Assignment (Inventors to Krisan Biotech)#page1.tif	
source=109559-715740 Executed Assignment (Inventors to Krisan Biotech)#page2.tif	
source=109559-715740 Executed Assignment (Inventors to Krisan Biotech)#page3.tif	

PATENT ASSIGNMENT			Docket Number 109559-669805 (758PCT US)
The undersigned:			
1. YaoLin SUN 13F., No. 339-12, Sec 2 Guangfu Rd., Fengshan Dist. Kaohsiung City 830 TW	2. LungHu WANG No. 102-2, Beishan Ln. Qijin Dist. Kaohsiung City 805 TW	3. ChangJung WU No. 28, Ln. 150, Youchang St. Nanxi Dist. Kaohsiung City 811 TW	4. ChuanDer HUANG No. 21, Aly. 11, Ln. 176, Sec. 1 Bei'an Rd., North Dist. Tainan City 794 TW
(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to <u>KRISAN BIOTECH CO., LTD.</u>, a Taiwanese company, having a place of business at <u>5F, No. 30, Lane 31, Section 1, Huangdon Road, Xinsai District, Tainan City 74146, Taiwan</u>, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment. NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee: 1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s): METHODS FOR MAKING AND USING ENDOXIFEN • for which application serial number <u>16/641,985</u> was filed on <u>February 25, 2020</u>, in the United States Patent and Trademark Office • for which a PCT application serial number <u>PCT/US2018/050272</u> was filed on September 10, 2020 in the U.S. Receiving Office of the Patent Cooperation Treaty (the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise). 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents. 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee. 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns. 5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith. 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns. 7. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement. IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:			

PATENT ASSIGNMENT		Docket Number 109559-669805 (758PCT US)
Date: 2021/01/08	Yao Lin Sun Yao Lin SUN	
Date: 2021/01/08	Lung Hu WANG Lung Hu WANG	
Date: 2021/01/08	Chang Jung WU Chang Jung WU	
Date: _____	ChuanDer HUANG	
RECEIVED AND AGREED TO BY ASSIGNEE: KRISAN BIOTECH CO., LTD.		
Date: 2021/01/08	Signature: <u>YuPei Wang</u> Name: YuPei Wang Title: C.E.O.	

PATENT ASSIGNMENT

Docket Number 38602-758601

WHEREAS, the undersigned:

- | | | | |
|--|---|---|---|
| 1. YaoLin SUN
13F., No. 339-12, Sec. 2
Guangfu Rd., Fengshan Dist.
Kaohsiung City 830
TW | 2. LungHu WANG
No. 102-2, Beishan Ln.
Qijin Dist.
Kaohsiung City 805
TW | 3. ChangJung WU
No. 28, Ln. 150, Youchang St.
Nanzi Dist.
Kaohsiung City 811
TW | 4. ChuanDer HUANG
No. 21, Aly. 11, Ln. 176, Sec. 1
Bei'an Rd., North Dist.
Tainan City 704
TW |
|--|---|---|---|

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

METHODS FOR MAKING AND USING ENDOXIFEN

for which a PCT application serial number PCT/US2018/050272 was filed on September 10, 2018, in the United States Receiving Office of the Patent Cooperation Treaty (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, KRISAN BIOTECH CO., LTD., a Taiwanese company, having a place of business at 5F, No. 30, Lane 31, Section 1, Huangdong Road, Xinshi District, Tainan City 74146, Taiwan (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 2018/09/26

YaoLin SUN

YaoLin SUN

Date: 2018/09/26

LungHu WANG

LungHu WANG

Date: 2018/09/26

ChangJung WU

ChangJung WU

Date: 2018/09/26

ChuanDer HUANG

ChuanDer HUANG

PATENT ASSIGNMENT	Docket Number 38602-758601
RECEIVED AND AGREED TO BY ASSIGNEE: KRISAN BIOTECH CO., LTD. Date: <u>2018/09/26</u> Signature: <u>CD. Huang</u> Name: ChuanDer Huang Title: President & CEO	